GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study.

ABSTRACT:

Background

Parkinson's disease is a progressive neurodegenerative disorder with no cure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have neuroprotective effects. However, long-term real-world studies are needed to clarify their potential impact on Parkinson's disease.

Methods

This nationwide cohort study included 33,462 patients (16,731 GLP-1RA initiators and 16,731 propensity score-matched dipeptidyl peptidase-4 inhibitor [DPP-4i] initiators) from 2007 to 2018, followed until 2022. Eligible participants were ≥ 50 years, had no prior cancer or Parkinson's disease, and were residents in Denmark for at least 10 years. Patients were followed until Parkinson's diagnosis, death, emigration, treatment discontinuation (no additional prescription within 180 days), swit

SUBMITTER: Gamborg M 

PROVIDER: S-EPMC11808555 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature